Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center

INTRODUCTION

A hyperinflammatory state is a posited driver of severe COVID-19 [1]. Elevations of IL-6 have been described in acute respiratory distress syndrome and cytokine release syndrome (CRS) [2,3]. Recently, IL-6-driven inflammation in severe COVID-19 was suggested, as increased levels were associated with mortality [4]. IL-6 blockade via tocilizumab, a humanized monoclonal antibody that targets the IL-6 receptor, has been proposed as a treatment for COVID-19 [5].

Peer-reviewed reports of tocilizumab use for COVID-19 are largely limited to retrospective case series from China [6,7] and Italy [8,9], as well as case reports [10–13]. Xu et al. reported improved inflammatory markers, oxygen requirements, and fever in 21 patients after tocilizumab treatment [6]. Luo et al.’s description of 15 patients included more critically ill patients and more measured results, with 20% mortality [7]. A prospective, open-label study from Italy reported clinical improvement and increased survival after tocilizumab [8], while a second study in Italy found no significant clinical improvement or mortality benefit following tocilizumab [9]. Given the paucity of data on tocilizumab use in COVID-19 in the United States, we evaluated 11 patients treated with tocilizumab for COVID-19. We detail their clinical characteristics before and after treatment and reconsider tocilizumab use in severe COVID-19.

METHODS

We performed a retrospective cohort study of patients with COVID-19 treated with tocilizumab at UNC Medical Center between March 21st and April 25th, 2020. Clinical data was extracted from the medical record. COVID-19 was diagnosed using nasopharyngeal swabs and reverse-transcriptase PCR (RT-PCR). IL-6 testing was conducted at Mayo Clinic Laboratories (Rochester, MN) using an electrochemiluminescence assay. Baseline IL-6 values for two patients were from a multi-cytokine panel (lower-limit of detection [LOD] of 5.0 pg/mL); all others were from a standalone IL-6 assay (LOD 1.8 pg/ml). Disease severity was defined according to the World Health Organization (WHO) COVID-19 clinical status scale with minor modification [14]. Descriptive statistics were calculated using JMP 15 and Wilcoxon signed rank test performed in GraphPad Prism 8. Data was visualized using the tidyverse package in R 3.6.0. The study was approved by the UNC Institutional Review Board.

RESULTS

Outcomes after tocilizumab

Tocilizumab was administered a median of one day (IQR 1-4) from admission and nine days (IQR 7-14) after symptom onset. Ten patients received a single tocilizumab dose, and one received two doses. Median dosage was 7.9 mg/kg. Two of six patients with available baseline IL-6 levels had low levels, one below the assay’s LOD (≤5 pg/mL) and another of 10.4 pg/mL. Four of five with available IL-6 levels after tocilizumab had IL-6 levels above the upper limit of quantification. IL-6 increased after tocilizumab in all four patients with matched baseline and post-tocilizumab testing.

CRP and fibrinogen decreased significantly after tocilizumab (Figure 1A, median CRP 211.6 vs. 19.7 mg/L [p=0.001] and fibrinogen 767 vs. 420 mg/dL [p=0.002] pre- and 5 days post-tocilizumab, respectively). Other laboratory markers did not show clear trends (Figure 1B). Temperature did not show obvious improvement (Figure 1C), and only three (27%) showed improvement in oxygen requirements (Figure 1D). At end of follow-up, patients were observed for a median of 17 days (range=7-34) after initial tocilizumab dose. Three died (27%); five (45%) remained in the intensive care unit (ICU) on mechanical ventilation, receiving vasopressors or hemodialysis; one (9%) was transferred from the ICU to floor status and weaned to room air; and two (18%) were discharged home without oxygen. Seven patients (64%) had minimally elevated liver function tests after tocilizumab administration. Two were diagnosed with ileus and two with bacterial pneumonia after tocilizumab administration; no serious adverse events were observed.

• Download figure
• Open in new tab

Figure 1. Laboratory and clinical outcomes of patients treated with tocilizumab

(A-B) Laboratory trends following tocilizumab. Medians (blue lines), interquartile ranges (IQR, blue shading), and reference ranges (dashed red lines). (C-D) Oxygen requirements and temperature trends, displayed using locally estimated scatterplot smoothing (orange lines). Patient #6 was treated with two doses of tocilizumab; time 0 refers to the time of initial administration.

DISCUSSION

While tocilizumab was recently described as a promising therapy for severe COVID-19, our findings raise questions about its use in critically ill patients [7]. We report data from patients with COVID-19 treated with tocilizumab at a United States academic center, almost all of whom required ICU care. CRP and fibrinogen improved after tocilizumab administration as previously reported [6–8], but improvement in disease severity or mortality were not observed. These findings, in addition to low baseline IL-6 levels observed in some patients, raise questions about tocilizumab use in patients presenting with severe or critical COVID-19, especially without baseline IL-6 data.

Important differences exist between our cohort and those from China and Italy [6–9]. Three of four studies had few patients requiring mechanical ventilation (n=2/21, n=4/32, and n=5/63 respectively) [6,8,9]; the fourth study did not report specific oxygen requirements but did include more patients reported as critically ill (n=7/15) [7]. Our cohort included higher rates of hypertension (73% versus 40% in Luo et al., 37% in Campochiaro et al., and 38% in Sciascia et al.); a majority were overweight or obese (91%). We also observed lower baseline IL-6 levels compared to those described in these cohorts, although IL-6 assays were conducted in different laboratories. While Sciascia et al. attribute observed survival benefit of tocilizumab treatment to early administration in their Italian cohort [8], we did not observe the same clinical improvement, despite tocilizumab administration within a median of one day of hospitalization. Our findings also demonstrate the challenge of defining CRS in COVID-19, especially in the absence of standardized IL-6 assays and limited data to support IL-6 thresholds for tocilizumab use.

Our findings contrast with most previous reports and do not provide clear evidence of clinical improvement after tocilizumab treatment in patients with severe COVID-19. Several explanations can be considered. First, our patients were more severely ill than previous cohorts. It is possible tocilizumab was administered too late to offer benefit. Second, our patient cohort was more racially and ethnically diverse and had more comorbidities, notably obesity and hypertension, than those in China and Italy. Third, improvements observed in prior, less severely ill cohorts, might have occurred as part of the normal disease process, with or without tocilizumab.

In conclusion, tocilizumab reduces inflammatory markers (CRP, fibrinogen), but it is unclear whether its activity leads to equally dramatic effects on clinical outcomes. Randomized controlled trials are essential to determine when, or if, tocilizumab should be used in severe COVID-19.

Funding

The authors report no designated funding for the project. CAR and CEM receive training support from the University of North Carolina at Chapel Hill Medical Scientist Training Program. CAR additionally receives training support from the National Institutes of Health MD/PhD Partnership Program.

Conflicts of interest

JBP reports research support outside the submitted work from Gilead Sciences and the World Health Organization, and non-financial support from Abbott Laboratories. CLG has received research support outside the submitted work from Viiv Healthcare and Gilead Sciences. SSC reports research support outside of the submitted work from Biomarck Pharmaceuticals.